AMR.Solutions

IDSA’s Faces of Antimicrobial Resistance (FAOR) report

Dear All:

This one appears to have been released on 7 Mar but it just crossed my desk today. In brief, IDSA has assembled 13 patient stories into a well-written and illustrated .pdf. The centerpiece of the paper is this graphical history of AMR shown below.  Well done to IDSA for pulling these stories together in an accessible format!

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx

The .pdf itself: http://www.idsociety.org/uploadedFiles/IDSA/FOAR/FOAR%20Report%201-up%20final.pdf
IDSA resource page: http://www.idsociety.org/Topic_Antimicrobial_Resistance/

Picture
Menu-01-01

Share

More Newsletters

AI-based drug discovery: Chemical vs. drugs (Part 4)

Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the original report has a new paper about identification of a narrow-spectrum compound with activity vs. Acinetobacter baumannii. Here are the links you’ll

WHO-UNEP-FAO-OIE Youth Engagement Working Group on AMR: Apply now!

“Education is the most powerful weapon we can use to change the world…” — Nelson Mandela Dear All, Regular readers will know my interest in developing the ecosystem of people who will work to address AMR over time (e.g., this interview with the founder of the Future Leaders Against AMR, my strong support for the

Reports calling for Pull: US GAO, Global AMR R&D Hub

Dear All, Two important reports for your awareness this afternoon. First, the Global AMR R&D hub have responded to a request from the G7 Finance and Health Ministers to provide an update to their 2022 progress report in advance of upcoming G7 meetings. As background, recall that the Finance Ministers in 2021 (during the UK G7

High Watermark for Pull Incentives (and more): Reflections on an amazing week!

Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …

More Newsletters
Subscribe

AMR.Solutions

Using ideas to connect, create, and inspire

Twitter Facebook Linkedin Envelope Instagram Youtube

Supported by the Wellcome Trust

Site Map

Scroll to Top